| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2016
(7 years ago) | |
Gadavist is owned by Bayer Hlthcare.
Gadavist contains Gadobutrol.
Gadavist has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Gadavist are:
- US5980864
- US5980864
Gadavist was authorised for market use on 18 December, 2013.
Gadavist is available in solution;intravenous dosage forms.
Gadavist can be used as contrast agent for magnetic resonance imaging.
Drug patent challenges can be filed against Gadavist from 15 March, 2015.
The generics of Gadavist are possible to be released after 12 July, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-801) | Jul 12, 2022 |
| New Indication(I-688) | Jun 11, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2016 |
| New Indication(I-731) | Apr 27, 2019 |
Drugs and Companies using GADOBUTROL ingredient
NCE-1 date: 15 March, 2015
Market Authorisation Date: 18 December, 2013
Treatment: Contrast agent for magnetic resonance imaging
Dosage: SOLUTION;INTRAVENOUS
GADAVIST family patents
